HANSOH PHARMA(03692)

31.940+0.780+2.50%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Hansoh Pharma’s B7-H3 ADC HS-20093 Delivers Statistically Significant Overall-Survival Benefit in Phase III Small Cell Lung Cancer Trial
  Bulletin Express · 19:43
  Hansoh Pharma’s B7-H3 ADC HS-20093 Delivers Statistically Significant Overall-Survival Benefit in Phase III Small Cell Lung Cancer Trial
- Hansoh Pharmaceutical - Hs-20,093 Meets Primary Endpoint in Phase Iii Sclc Trial
  THOMSON REUTERS · 19:36
  Hansoh Pharmaceutical - Hs-20,093 Meets Primary Endpoint in Phase Iii Sclc Trial
- GSK Flags Availability of Hansoh Pharma Update on Ris-rez Phase III China Trial Results
  Reuters · 19:08
  GSK Flags Availability of Hansoh Pharma Update on Ris-rez Phase III China Trial Results
- Hansoh Pharma Says Hs-20093 Meets Overall Survival Endpoint in Phase 3 Small Cell Lung Cancer Trial
  Reuters · 18:47
  Hansoh Pharma Says Hs-20093 Meets Overall Survival Endpoint in Phase 3 Small Cell Lung Cancer Trial
- Movement Alert｜Hansoh Pharmaceutical Rises 3.08% in Regular Trading, Innovation Drug Payment Reform Catalyzes Sector-Wide Rally
  Market Focus · 10:09
  Movement Alert｜Hansoh Pharmaceutical Rises 3.08% in Regular Trading, Innovation Drug Payment Reform Catalyzes Sector-Wide Rally
- Hansoh Pharmaceutical Group Stock Slips 3.0% in Hong Kong
  Dow Jones · 07-09 16:32
  Hansoh Pharmaceutical Group Stock Slips 3.0% in Hong Kong
- Movement Alert｜Hansoh Pharmaceutical Falls 3.05% in Regular Trading, Trading at HK$31.2
  Market Focus · 07-09 13:33
  Movement Alert｜Hansoh Pharmaceutical Falls 3.05% in Regular Trading, Trading at HK$31.2
- Movement Alert｜Hansoh Pharmaceutical Rises 3.07% in Regular Trading, Innovative Drug Pipeline Catalysts Continue Amid Sector Rebound
  Market Focus · 07-08 09:50
  Movement Alert｜Hansoh Pharmaceutical Rises 3.07% in Regular Trading, Innovative Drug Pipeline Catalysts Continue Amid Sector Rebound
- Hansoh Pharmaceutical Group Stock Sheds 4.2% in Hong Kong
  Dow Jones · 07-07
  Hansoh Pharmaceutical Group Stock Sheds 4.2% in Hong Kong
- Movement Alert｜Hansoh Pharmaceutical Falls 3.24% in Regular Trading, Pharmaceutical Sector Retreats After Prior Session Gains
  Market Focus · 07-07
  Movement Alert｜Hansoh Pharmaceutical Falls 3.24% in Regular Trading, Pharmaceutical Sector Retreats After Prior Session Gains
- Movement Alert｜Hansoh Pharma Rises 3.74% in Regular Trading, HS-20136-2 Clinical Trial Approvals Continue to Drive Momentum Amid Pharma Sector Strength
  Market Focus · 07-06
  Movement Alert｜Hansoh Pharma Rises 3.74% in Regular Trading, HS-20136-2 Clinical Trial Approvals Continue to Drive Momentum Amid Pharma Sector Strength
- Hansoh Pharmaceutical Group (SEHK:3692) Wins Trial Approval, Is It Fully Priced?
  Simply Wall St. · 07-05
  Hansoh Pharmaceutical Group (SEHK:3692) Wins Trial Approval, Is It Fully Priced?
- Hansoh Pharma Keeps Share Base Steady at 6.06 Billion in June, Details HKD 4.68 Billion Convertible Bonds
  Bulletin Express · 07-03
  Hansoh Pharma Keeps Share Base Steady at 6.06 Billion in June, Details HKD 4.68 Billion Convertible Bonds
- Movement Alert｜Hansoh Pharmaceutical Rises 4.41% in Regular Trading, HS-20136-2 Injection Receives Two Clinical Trial Approvals from NMPA
  Market Focus · 07-03
  Movement Alert｜Hansoh Pharmaceutical Rises 4.41% in Regular Trading, HS-20136-2 Injection Receives Two Clinical Trial Approvals from NMPA
- Hansoh Pharmaceutical Receives Dual NMPA Approvals for HS-20136-2 Injection Trials in Diabetes and Weight Management
  Bulletin Express · 07-02
  Hansoh Pharmaceutical Receives Dual NMPA Approvals for HS-20136-2 Injection Trials in Diabetes and Weight Management
- Hansoh Pharma's HS-20136-2 Injection Receives NMPA Approval for Clinical Trials
  Stock News · 07-02
  Hansoh Pharma's HS-20136-2 Injection Receives NMPA Approval for Clinical Trials
- Hansoh Pharma Says China NMPA Clears Hs-20136-2 Injection for Clinical Trials in Type 2 Diabetes
  Reuters · 07-02
  Hansoh Pharma Says China NMPA Clears Hs-20136-2 Injection for Clinical Trials in Type 2 Diabetes
- Hansoh Pharmaceutical - Clinical Trial Approvals for Hs-20136-2 Injection Issued- by Nmpa
  THOMSON REUTERS · 07-02
  Hansoh Pharmaceutical - Clinical Trial Approvals for Hs-20136-2 Injection Issued- by Nmpa
- Hansoh Pharmaceutical Group Stock Rises 6.4% in Hong Kong
  Dow Jones · 07-02
  Hansoh Pharmaceutical Group Stock Rises 6.4% in Hong Kong
- Movement Alert｜Hansoh Pharmaceutical Rises 6.01% in Regular Trading, Pemosatide Injection Approval Coupled with Pharma Sector Rally
  Market Focus · 07-02
  Movement Alert｜Hansoh Pharmaceutical Rises 6.01% in Regular Trading, Pemosatide Injection Approval Coupled with Pharma Sector Rally
Company Profile
Company Name
HANSOH PHARMA
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
- -
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.
- 04-28
  Annual Report
  ANNUAL REPORT 2025
  ANNUAL REPORT 2025

1D
5D
Day
Week
Month

Loading ...

High

32.940

Open

31.180

Volume%

0.65

Low

30.860

31.160

T/O Rate

0.20%

To The Moon

HANSOH PHARMA(03692)

Company Profile

Most Discussed